Leerink Partners analyst Joseph Schwartz maintains Mereo BioPharma Group (NASDAQ:MREO) with a Outperform and raises the price target from $6 to $8.
Leerink Partners Maintains Outperform on Mereo BioPharma Group, Raises Price Target to $8
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.